Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioGend Therapeutics CoROCO:6733 -2.50%73 Gross Margin % is 69.14% as of Dec. 2025, which is 4% below its 10-year median of 72.03. GuruFocus rates ROCO:6733 with a GF Score™ of 73/100 and a GF Value™ of NT$70.22 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 732 Biotechnology companies, BioGend Therapeutics Co ranks better than 62.16% on this metric.
ROCO:6733's Gross Margin % is ranked better than 62.16% of 732
companies
in the Biotechnology industry
Industry Median: 60.905
vs ROCO:6733: 72.03
BioGend Therapeutics Co had a gross margin of 69.14% for the quarter that ended in Dec. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for BioGend Therapeutics Co was 13.00% per year.
BioGend Therapeutics Co (ROCO:6733) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
BioGend Therapeutics Co had a gross margin of 69.14% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
BioGend Therapeutics Co Gross Margin % Related Terms
BioGend Therapeutics Co Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6733 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, BioGend Therapeutics Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioGend Therapeutics Co Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioGend Therapeutics Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where BioGend Therapeutics Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
BioGend Therapeutics Co (ROCO:6733) has a Gross Margin % of 69.14% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on BioGend Therapeutics Co and its competitors. This is near median its historical median of 72.03. Over the past decade, BioGend Therapeutics Co's Gross Margin % has ranged from 12.66 to 81.54. According to the industry distribution chart, BioGend Therapeutics Co ranks #277 out of 732 companies in the Biotechnology industry, placing it in the top 37.8%.
Is BioGend Therapeutics Co's Gross Margin % too high?
BioGend Therapeutics Co's current Gross Margin % of 69.14% is near median its 10-year median of 72.03. Over the past 10 years, this metric has ranged from a low of 12.66 to a high of 81.54. The Biotechnology industry median Gross Margin % is 60.91. BioGend Therapeutics Co's value of 69.14% is 13.5% above this industry median. Based on the distribution chart, BioGend Therapeutics Co ranks #277 out of 732 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BioGend Therapeutics Co has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioGend Therapeutics Co's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioGend Therapeutics Co ranks #277 out of 732 companies for Gross Margin %. This puts BioGend Therapeutics Co in the upper half of its industry. The industry median Gross Margin % is 60.91. BioGend Therapeutics Co's value of 69.14% is 13.5% above this benchmark. Historically, BioGend Therapeutics Co's own Gross Margin % has ranged from 12.66 to 81.54 over the past decade. While the company's 10-year median is 72.03 vs. the industry median of 60.91, BioGend Therapeutics Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioGend Therapeutics Co's current Gross Margin % of 69.14% is 13.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on BioGend Therapeutics Co and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioGend Therapeutics Co's current Gross Margin % is 69.14%, which is near median its own 10-year median of 72.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGend Therapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, BioGend Therapeutics Co (ROCO:6733) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$70.22, compared to a current price of NT$25.35 — trading 63.9% below its estimated fair value. The current Gross Margin % is 69.14%, which is near median its 10-year median of 72.03 and 13.5% above the Biotechnology industry median of 60.91. BioGend Therapeutics Co's overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For BioGend Therapeutics Co (ROCO:6733), the current Gross Margin % is 69.14% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioGend Therapeutics Co (ROCO:6733) Overvalued in 2026?
Based on GuruFocus' analysis, BioGend Therapeutics Co stock appears to be undervalued.
The current stock price of NT$25.35 is trading 63.9% below its estimated GF Value™ of NT$70.22.
GuruFocus considers BioGend Therapeutics Co to be Significantly Undervalued.
Key valuation signals for ROCO:6733:
Gross Margin %: 69.14% (near median its 10-year median of 72.03)
GF Value™: NT$70.22 vs. price of NT$25.35 (63.9% below fair value)
Industry Position: 13.5% above the Biotechnology median (#277 of 732)
No single metric tells the full story. See the ROCO:6733 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioGend Therapeutics Co Ltd is a Taiwan-based company involved in the research and development of orthopedic medical equipment and related products, and the sale of related products. It is involved in the research and development of inventive cartilage repair technology and products, adipose stem cell extraction technology, and others. Geographically, the company generates a majority of its revenue from Taiwan, followed by China, Malaysia, and other regions.
73GF Score
Get the complete analysis for ROCO:6733
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6733 has been successfully added to your 
